Vanguard Global Advisers’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
Other funds holding RNAC
6CM
Vanguard Global Advisers's RNAC Position: Q3 2026 in Review
Vanguard Global Advisers increased its Cartesian Therapeutics (RNAC) stake by 1.3% in Q3 2026, buying an estimated $409 and bringing the position to 3,677 shares worth $26.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3271.
Vanguard Global Advisers first reported a position in RNAC in Q1 2026 and has held it in 3 quarters since. The position peaked at $37.8K in Q2 2026. 100 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.
- Vanguard Global Advisers held 3,677 shares of Cartesian Therapeutics worth $26.5K as of Q3 2026.
- Vanguard Global Advisers bought 47 Cartesian Therapeutics shares in Q3 2026, an estimated $409.
- Cartesian Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3271 holding.
- Vanguard Global Advisers first reported a position in Cartesian Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Cartesian Therapeutics position peaked at $37.8K in Q2 2026.
- 100 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.